Fulgent Genetics, Inc.
FLGT Healthcare Diagnostics & Research
Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.
Follow FLGT
Fulgent Genetics, Inc. (FLGT) Altman Z-score
Fulgent Genetics, Inc.'s Altman Z-score for fiscal 2025 is 5.63, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 5.63 | 0.96 |
| FY2024 | 4.68 | (1.24) |
| FY2023 | 5.91 | (0.86) |
| FY2022 | 6.78 | (12.67) |
| FY2021 | 19.45 | 11.09 |
| FY2020 | 8.36 | (15.66) |
| FY2019 | 24.02 | 12.33 |
| FY2018 | 11.69 | (3.16) |
| FY2017 | 14.85 | (11.38) |
| FY2016 | 26.24 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.38 | — | 0.46 | |
| Retained earnings / total assets | 0.44 | — | 0.61 | |
| EBIT / total assets | (0.08) | — | −0.25 | |
| Market value of equity / total liabilities | 7.57 | — | 4.54 | |
| Sales / total assets | 0.27 | — | 0.27 | |
| Altman Z-score | Safe zone | 5.63 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 14.32 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| WGS GeneDx Holdings Corp. compare | 7.8× |
| CSTL Castle Biosciences, Inc. compare | 6.7× |
| FLGT Fulgent Genetics, Inc. | 5.6× |
| PSNL Personalis, Inc. compare | 3.4× |
| NEO NeoGenomics, Inc. compare | 1.8× |
| OPK OPKO Health, Inc. compare | −0.4× |
| MYGN Myriad Genetics, Inc. compare | −1.5× |
| XGN Exagen Inc. compare | −4.6× |
| BDSX Biodesix, Inc. compare | −7.5× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets